Level D· Scientific groundwork from lab and animal studiesLaboratory StudyPubMedOpen access

Adipose-derived mesenchymal stromal cells decrease prion-induced glial inflammation in vitro.

Hay AJD., Murphy TJ., Popichak KA., Zabel MD., Moreno JA.

Laboratory Study on Neuroinflammation, Chronic Inflammation, published in Sci Rep (2022) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Laboratory Study
Journal
Sci Rep (2022)
Country
England
Reported sample size
—
Source database
PubMed
PMID
36581683
PMCID
PMC9800558
DOI
10.1038/s41598-022-26628-7
Citations
8

Abstract (original English)

Prion diseases are characterized by the cellular prion protein, PrP C , misfolding and aggregating into the infectious prion protein, PrP Sc , which leads to neurodegeneration and death. An early sign of disease is inflammation in the brain and the shift of resting glial cells to reactive astrocytes and activated microglia. Few therapeutics target this stage of disease. Mesenchymal stromal cells produce anti-inflammatory molecules when exposed to inflammatory signals and damaged tissue. Here, we show that adipose-derived mesenchymal stromal cells (AdMSCs) migrate toward prion-infected brain homogenate and produce the anti-inflammatory molecules transforming growth factor β (TGFβ) and tumor necrosis factor-stimulated gene 6 (TSG-6). In an in vitro model of prion exposure of both primary mixed glia and BV2 microglial cell line, co-culturing with AdMSCs led to a significant decrease in inflammatory cytokine mRNA and markers of reactive astrocytes and activated microglia. This protection against in vitro prion-associated inflammatory responses is independent of PrP Sc replication. These data support a role for AdMSCs as a beneficial therapeutic for decreasing the early onset of glial inflammation and reprogramming glial cells to a protective phenotype.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
HumansPrionsPrion ProteinsNeurogliaPrion DiseasesMicrogliaMesenchymal Stem CellsInflammation

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research